Gavi, Bavarian Nordic Secures 500,000 Mpox Vaccine Doses For Africa

Gavi has signed an agreement with Bavarian Nordic to secure 500,000 doses of Mpox vaccines for Africa According to a statement from Gavi yesterday, the availability of all 500,000 doses has been secured for 2024.

The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health emergencies.

Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance has announced an advance purchase agreement (APA) to secure 500,000 doses of the MVABN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the Mpox outbreak. The doses will be delivered this year.

The vaccines will be funded by Gavi’s First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health emergencies.

The MVA-BN vaccine received prequalification from the WHO on September 13, and Bavarian Nordic will be ready to supply the vaccines pending the signing of a supply agreement with UNICEF, Gavi’s alliance partner, which will be delivering these doses.

“The First Response Fund was designed in collaboration with Gavi donors and partners specifically to provide rapid early funding for emergencies such as Mpox.

“Using it today to fund the first direct transaction for vaccines in support of equitable access and the global response, just over a month since Mpox was declared a public health emergency, takes us a long way towards our goal of protecting those most at risk,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance.